Evidence map›Paper›PMID 34155350›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.

Ingrid Ferreira, Alastair Droop, Olivia Edwards, Kim Wong, Victoria Harle, Omar Habeeb, Deepa Gharpuray-Pandit, Joseph Houghton, Katharina Wiedemeyer, Thomas Mentzel and 13 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy.medRxiv : the preprint server for health sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Pleomorphic Dermal Sarcoma With Metastasis to the Lung: A Case Report.The American Journal of dermatopathology · 2023
    Article
  17. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  18. Review
  19. Biochemistry and biophysics reports · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 9 countries.

Ingrid FerreiraExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.ORCID 0000-0002-4321-5250
Alastair DroopExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.ORCID 0000-0001-7695-7480
Olivia EdwardsExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Kim WongExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Victoria HarleExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Omar HabeebDepartment of Anatomic Pathology, Middlemore Hospital, Auckland, NZ, New Zealand.ORCID 0000-0003-4647-3463
Deepa Gharpuray-PanditDepartment of Cellular Pathology, Royal Preston Hospital, Preston, UK.
Joseph HoughtonDepartment of Pathology, Royal Victoria Hospital, Belfast, Ireland.
Katharina WiedemeyerDepartment of Dermatology, University of Heidelberg, Heidelberg, Germany.
Thomas MentzelDermatopathology Friedrichshafen, Friedrichshafen, Germany.
Steven D BillingsDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-2278-5908
Jennifer S KoDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-0629-775X
Laszlo FüzesiCenter for Pathology, Robert-Weixler-Straße 48a, Kempten, Germany.
Kathleen MulhollandDepartment of Pathology, Altnagelvin Area Hospital, Londonderry, UK.
Ivana Kuzmic PrusacDepartment of Pathology, University Hospital Split and Split University School of Medicine, Split, Croatia.
Bernadette Liegl-AtzwangerDiagnostic and Research Centre for Molecular Biomedicine, Diagnostic and Research Centre for Pathology, Translational Sarcoma Pathology, Comprehensive Cancer Centre Subunit Sarcoma, Medical University Graz, Graz, Austria.ORCID 0000-0003-2229-5535
Nicolas de Saint AubainDepartment of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Helen CaldwellDivision of Pathology, Cancer Research UK Edinburgh Centre, The University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, UK.
Laura RivaExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Louise van der WeydenExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Mark J ArendsDivision of Pathology, Cancer Research UK Edinburgh Centre, The University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, UK.ORCID 0000-0002-6826-8770
Thomas BrennDepartment of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. thomas.brenn@ucalgary.ca.ORCID 0000-0002-0089-0352
David J AdamsExperimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Wellcome Sanger Institute · GBCleveland Clinic · USEdinburgh Cancer Research · GBUniversité Libre de Bruxelles · BEUniversity of Calgary · CADermatopathologie Friedrichshafen · DEMedical University of Graz · ATMiddlemore Hospital · NZRoyal Preston Hospital · GBRoyal Victoria Eye and Ear Hospital · IEUniversity of Split · HRUniversity of Ulster · GB

Funding

Medical Research Council MR/S00386X/2Medical Research Council MR/V000292/1
6 · The paper itself

Abstract

Dedifferentiation and transdifferentiation are rare and only poorly understood phenomena in cutaneous melanoma. To study this disease more comprehensively we have retrieved 11 primary cutaneous melanomas from our pathology archives showing biphasic features characterized by a conventional melanoma and additional areas of de-/trans-differentiation as defined by a lack of immunohistochemical expression of all conventional melanocytic markers (S-100 protein, SOX10, Melan-A, and HMB-45). The clinical, histologic, and immunohistochemical findings were recorded and follow-up was obtained. The patients were mostly elderly (median: 81 years; range: 42-86 years) without significant gender predilection, and the sun-exposed skin of the head and neck area was most commonly affected. The tumors were deeply invasive with a mean depth of 7 mm (range: 4-80 mm). The dedifferentiated component showed atypical fibroxanthoma-like features in the majority of cases (7), while additional rhabdomyosarcomatous and epithelial transdifferentiation was noted histologically and/or immunohistochemically in two tumors each. The background conventional melanoma component was of desmoplastic (4), superficial spreading (3), nodular (2), lentigo maligna (1), or spindle cell (1) types. For the seven patients with available follow-up data (median follow-up period of 25 months; range: 8-36 months), two died from their disease, and three developed metastases. Next-generation sequencing of the cohort revealed somatic mutations of established melanoma drivers including mainly NF1 mutations (5) in the conventional component, which was also detected in the corresponding de-/trans-differentiated component. In summary, the diagnosis of primary cutaneous de-/trans-differentiated melanoma is challenging and depends on the morphologic identification of conventional melanoma. Molecular analysis is diagnostically helpful as the mutated gene profile is shared between the conventional and de-/trans-differentiated components. Importantly, de-/trans-differentiation does not appear to confer a more aggressive behavior.

Indexed as

GenomicsAdultAgedAged, 80 and overBiomarkers, TumorCell DifferentiationDiagnosis, DifferentialDNA, NeoplasmFemaleHigh-Throughput Nucleotide SequencingHumansMaleMelanomaMiddle AgedNeoplasm ProteinsNeurofibromin 1Biomarkers, TumorDNA, NeoplasmNeoplasm ProteinsNeurofibromin 1NF1 protein, human

Identifiers

PMID34155350
OpenAlexW3175515112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.